Biovista’s drug safety search aids clinical outcomes.
Interview to Bio-IT World
By Kevin Davies
June 8, 2011 | Biovista began as a hobby,” admits the company’s eloquent president, Aris Persidis. But after “dabbling” with the firm for a few years, Persidis incorporated the company in the United States in 2005. Headquartered in Charlottesville, Virginia, Biovista is becoming an important partner in the drug safety and repositioning arena.
Biovista started out in the mid 1990s as a business intelligence company, but Aris, a biochemist by training, and his cofounder (and brother) Andreas, a naval architect by training, would spend long hours debating whether new engineering approaches could answer some complicated biological questions, such as: Can one figure out a side effect before it happens, or deduce a mechanism in a disease when you don’t have a drug?
These two questions go hand in hand, says Persidis. “We can’t conceive contemplating efficacy and not simultaneously how it will impact safety and adverse events,” he says. “We quickly needed a technology to agnostically develop safety and efficacy simultaneously.”
Read More…